• Citer

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

par Turner, Nicholas C;Swift, Claire;Kilburn, Lucy;Fribbens, Charlotte;Beaney, Matthew;Garcia-Murillas, Isaac;Budzar, Aman A.U.;Robertson, John F R;Gradishar, William;Piccart-Gebhart, Martine ;Schiavon, Gaia;Bliss, Judith M;Dowsett, Mitch;Johnston, Stephen Rd D S.;Chia, Stephen
Référence Clinical cancer research, 26, 19, page (5172-5177)
Publication Publié, 2020-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Auteur:	Turner, Nicholas C; Swift, Claire; Kilburn, Lucy; Fribbens, Charlotte; Beaney, Matthew; Garcia-Murillas, Isaac; Budzar, Aman A.U.; Robertson, John F R; Gradishar, William; Piccart-Gebhart, Martine; Schiavon, Gaia; Bliss, Judith M; Dowsett, Mitch; Johnston, Stephen Rd D S.; Chia, Stephen
Informations sur la publication:	Clinical cancer research, 26, 19, page (5172-5177)
Statut de publication:	Publié, 2020-10
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-20-0224
	info:scp/85098632435
	info:pmid/32546646